Arthritis, RheumatoidNCT03063593
UK Infinity, Post-Market Clinical Follow-up Study
An observational study of Arthritis, Rheumatoid and Post-traumatic Osteoarthritis, run by Stryker Trauma and Extremities at 12 sites in United Kingdom.
Trial summary
Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System Number of Subjects 500… Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
- How many people
- 500 participants
- Where
- 12 sitesUnited Kingdom
- Study dates
- 29 Apr 2016to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System
Who may be able to join
- Subjects to be included in the study must meet all of the following criteria:
- Be 21 years of age at the time of surgery;
- Diagnosed with unilateral and/or bilateral ankle joint disease;
- Diagnosed with ankle joint damage from rheumatoid arthritis, post-traumatic, or degenerative arthritis; Willing and able to consent to participate (written, informed consent / witnessed verbal consent) Willing and able to attend the requested follow-up visits;
- Subjects determined by the Investigator to be an appropriate candidate for the INFINITY® Total Ankle System
Who cannot join
- Subjects will be excluded from the study if they meet any of the following criteria:
- Subjects with an ankle condition, as determined by the investigator, to be an inappropriate candidate for a total ankle replacement;
- Subjects requiring revision total ankle replacement of the ankle being considered for study
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
United Kingdom12 sites
University Hairmyres Hospital
Bothwell, Scotland, G71 8BB
Royal Bournemouth Hosptial
Bournemouth, Dorset, BH7 7DW
North Bristol NHS Trust Southmead Hospital
Bristol, BS105NB
Royal Infirmary of Edinburgh
Edinburgh, EH16 4SA
Royal Devon and Exeter NHS Foundation Trust
Exeter, EX2 5DW
Royal National Orthopaedic Hospital
Middlesex, HA7 4LP
North Tyneside General Hospital
Newcastle upon Tyne, NE29 8NH
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG5 1PB
RJAH Orthopaedic Hospital
Oswestry, Shropshire, SY10 7AG
Sheffield Teaching Hospital
Sheffield, South Yorksire, S5 7AU
Torbay Hospital
Torquay, Devon, TQ2 7AA
Wrightington Hospital
Wigan, WN6 9EP
About this study
Official title: UK Multi-Centre, Observational, Post-Market Clinical Follow-up of the INFINITY® Total Ankle System
Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System Number of Subjects 500 with 10 sites
Read the detailed description
Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System N Subjects 500 with 10 sites Follow-Up Schedule Subject enrollment will consist of a Pre-operative, Operative, 6 months, 1 yr., 2 yr., 5yr., 7 yr., 10 yr., and an unscheduled visit as needed.
Primary Objective Evaluate the long-term survivorship of the INFINITY® implant over 10 years
Secondary Objective(s) Secondary objectives assessed will be to:
- Identify and assess the implant for component loosening and/or subsidence, any osteolysis and/or cyst formation through radiographic evaluation early and throughout the lifetime of the implant.
- Compare the improvements in self-reported pain and social interaction for quality of life measures from pre-op through 10 years post operatively; assessed by EuroQol (EQ5D5L).
- Compare pain and functional improvement in the Ankle Osteoarthritis Score (AOS), which is a visual analogue scale specifically designed as a modification of the Foot Function Index.
- Compare the improvement in self-reported pain-free function scores from pre-op through 10 years post-operatively, assessed by the Manchester Oxford Foot Questionnaire (MOXFQ) walking/standing scores.
- Identify and report the safety of the implant in terms of complications and adverse events.
Inclusion Criteria Subjects to be included in the study must meet all of the following criteria:
- Be 21 years of age at the time of surgery;
- Diagnosed with unilateral and/or bilateral ankle joint disease;
- Diagnosed with ankle joint damage from rheumatoid arthritis, post-traumatic, or degenerative arthritis; Willing and able to consent to participate (written, informed consent / witnessed verbal consent) Willing and able to attend the requested follow-up visits;
- Subjects determined by the Investigator to be an appropriate candidate for the INFINITY® Total Ankle System
Exclusion Criteria Subjects will be excluded from the study if they meet any of the following criteria:
- Subjects with an ankle condition, as determined by the investigator, to be an inappropriate candidate for a total ankle replacement;
- Subjects requiring revision total ankle replacement of the ankle being considered for study
- Medical subject headings
- Arthritis, Rheumatoid, Osteoarthritis
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome Measure survivorship at 10 years
The primary outcome measure of this post-market clinical observational study is to collect data relating to the INFINITY® Total Ankle System performance/survivorship at up to 10 years.
Measured: 10 Years
Secondary outcomes (4)
EQ5D-EuroQol-questionnaire
Compare the improvement in self-reported pain and social interaction for quality of life measures
Measured: From pre-op through 10 years
Ankle Osteoarthritis Score (AOS)-questionnaire
Self-reported to compare pain and functional improvement, which is a visual analogue scale specifically designed as a modification of the Foot function Index
Measured: From Pre-op through 10 years
Manchester Oxford Foot Questionnaire (MOXFQ)-questionnaire
Compare the improvement in self-reported pain-free function scores (walking/standing scores)
Measured: From Pre-op through 10 years
Radiographic evaluation-physician reported questionnaire
identify and assess the implant for component loosening and/or subsidence, any osteolysis and/or cyst formation
Measured: From Pre-op through 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2017
- Study start29 Apr 2016
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arthritis, RheumatoidStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stryker Trauma and Extremities
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- David Townshend, MD, Study chair, Northumbria TrustRebecca Gibson, Study director, Stryker Trauma & Extremeties
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03063593
- Sponsor's protocol ID
- UK15-TAR-001
- Status last verified
- Jan 2026
- First submitted
- 15 Feb 2017
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- UK Multi-Centre, Observational, Post-Market Clinical Follow-up of the INFINITY® Total Ankle System
- ClinicalTrials.gov ID
- NCT03063593
- Acronym / sponsor ID
- UK15-TAR-001
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Stryker Trauma and ExtremitiesIndustry (pharma, biotech, devices)
- Study start
- 29 Apr 2016 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 24 Feb 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System Number of Subjects 500 with 10 sites
Detailed description
Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System N Subjects 500 with 10 sites Follow-Up Schedule Subject enrollment will consist of a Pre-operative, Operative, 6 months, 1 yr., 2 yr., 5yr., 7 yr., 10 yr., and an unscheduled visit as needed.
Primary Objective Evaluate the long-term survivorship of the INFINITY® implant over 10 years
Secondary Objective(s) Secondary objectives assessed will be to:
- Identify and assess the implant for component loosening and/or subsidence, any osteolysis and/or cyst formation through radiographic evaluation early and throughout the lifetime of the implant.
- Compare the improvements in self-reported pain and social interaction for quality of life measures from pre-op through 10 years post operatively; assessed by EuroQol (EQ5D5L).
- Compare pain and functional improvement in the Ankle Osteoarthritis Score (AOS), which is a visual analogue scale specifically designed as a modification of the Foot Function Index.
- Compare the improvement in self-reported pain-free function scores from pre-op through 10 years post-operatively, assessed by the Manchester Oxford Foot Questionnaire (MOXFQ) walking/standing scores.
- Identify and report the safety of the implant in terms of complications and adverse events.
Inclusion Criteria Subjects to be included in the study must meet all of the following criteria:
- Be 21 years of age at the time of surgery;
- Diagnosed with unilateral and/or bilateral ankle joint disease;
- Diagnosed with ankle joint damage from rheumatoid arthritis, post-traumatic, or degenerative arthritis; Willing and able to consent to participate (written, informed consent / witnessed verbal consent) Willing and able to attend the requested follow-up visits;
- Subjects determined by the Investigator to be an appropriate candidate for the INFINITY® Total Ankle System
Exclusion Criteria Subjects will be excluded from the study if they meet any of the following criteria:
- Subjects with an ankle condition, as determined by the investigator, to be an inappropriate candidate for a total ankle replacement;
- Subjects requiring revision total ankle replacement of the ankle being considered for study
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY® Total Ankle System
Key inclusion criteria (5 listed)
- Be 21 years of age at the time of surgery;
- Diagnosed with unilateral and/or bilateral ankle joint disease;
- Diagnosed with ankle joint damage from rheumatoid arthritis, post-traumatic, or degenerative arthritis; Willing and able to consent to participate (written, informed consent / witnessed verbal consent) Willing and able to attend the requested follow-up visits;
- Subjects determined by the Investigator to be an appropriate candidate for the INFINITY® Total Ankle System
Key exclusion criteria (3 listed)
- Subjects with an ankle condition, as determined by the investigator, to be an inappropriate candidate for a total ankle replacement;
- Subjects requiring revision total ankle replacement of the ankle being considered for study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary Outcome Measure survivorship at 10 years
Time frame: 10 Years
The primary outcome measure of this post-market clinical observational study is to collect data relating to the INFINITY® Total Ankle System performance/survivorship at up to 10 years.
4 secondary outcomes
EQ5D-EuroQol-questionnaire
Time frame: From pre-op through 10 years
Ankle Osteoarthritis Score (AOS)-questionnaire
Time frame: From Pre-op through 10 years
Manchester Oxford Foot Questionnaire (MOXFQ)-questionnaire
Time frame: From Pre-op through 10 years
Radiographic evaluation-physician reported questionnaire
Time frame: From Pre-op through 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Arthritis, Rheumatoid
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Active, not recruitingObservational study
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
Rheumatoid Arthritis, Ankylosing Spondylitis
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Not yet recruitingPhase 2
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Townshend, MD study chair
Northumbria Trust
Rebecca Gibson study director
Stryker Trauma & Extremeties
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arthritis, Rheumatoid and Post-traumatic Osteoarthritis, run by Stryker Trauma and Extremities at 12 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome Measure survivorship at 10 years (time frame: 10 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.